Acadian Asset Management LLC Chemo Centryx, Inc. Transaction History

Acadian Asset Management LLC

$32.5 Billion
Q2 2024

Shares

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 12, 2021	SELL	$13.18 - $19.83 $80,687 - $121,399	-6,122 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$9.59 - $50.88 $58,709 - $311,487	6,122 New	6,122 $82,000
Q2 2020 Aug 12, 2020	SELL	$38.58 - $65.07 $2.82 Million - $4.76 Million	-73,128 Closed	0 $0
Q1 2020 May 11, 2020	SELL	$32.73 - $50.78 $4.86 Million - $7.54 Million	-148,549 Reduced 67.01%	73,128 $2.94 Million
Q4 2019 Feb 06, 2020	SELL	$6.81 - $39.55 $2.41 Million - $14 Million	-353,293 Reduced 61.45%	221,677 $8.77 Million
Q3 2019 Nov 07, 2019	SELL	$6.47 - $8.96 $1.61 Million - $2.22 Million	-248,110 Reduced 30.14%	574,970 $3.9 Million
Q2 2019 Aug 08, 2019	BUY	$8.31 - $14.85 $398,522 - $712,161	47,957 Added 6.19%	823,080 $7.66 Million
Q1 2019 May 09, 2019	SELL	$10.01 - $13.89 $434,093 - $602,353	-43,366 Reduced 5.3%	775,123 $10.8 Million
Q4 2018 Feb 07, 2019	SELL	$9.15 - $12.26 $712,702 - $954,943	-77,891 Reduced 8.69%	818,489 $8.93 Million
Q3 2018 Oct 30, 2018	BUY	$10.49 - $13.72 $1.61 Million - $2.1 Million	153,082 Added 20.59%	896,380 $11.3 Million
Q2 2018 Jul 24, 2018	BUY	$10.62 - $13.98 $2.35 Million - $3.1 Million	221,434 Added 42.43%	743,298 $9.79 Million
Q1 2018 Apr 12, 2018	BUY	$5.9 - $14.99 $489,853 - $1.24 Million	83,026 Added 18.92%	521,864 $7.1 Million
Q4 2017 Jan 18, 2018	SELL	$5.53 - $8.42 $322,714 - $491,365	-58,357 Reduced 11.74%	438,838 $2.61 Million
Q3 2017 Oct 13, 2017	BUY	$6.5 - $10.69 $3.23 Million - $5.32 Million	497,195	497,195 $3.69 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.